Myriad Genetics Expects Higher Q4 Revenue, Provides 2025 Guidance

Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12.79 USD | +1.75% |
|
-0.97% | -6.60% |
Feb. 05 | Myriad Genetics Get 2 Patents for Molecular Residual Disease Assay | MT |
Feb. 05 | Myriad Genetics Announces Two New Patents Granted For Its Molecular Residual Disease (MRD) Assay | RE |